SLCTR/2013/024
Completed
N/A
Randomized, double blind, controlled, comparative clinical trial on efficacy and safety of intralesional 10% and 15% hypertonic saline vs sodium stiboglucate in cutaneous leishmaniasis
Teaching Hospital Anuradhapura0 sitesTBD
ConditionsCutaneous leishmaniasis
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Cutaneous leishmaniasis
- Sponsor
- Teaching Hospital Anuradhapura
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All consenting patients presenting to the Skin Clinic, Teaching Hospital, Anuradhapura with a clinical diagnosis of cutaneous leishmaniasis, confirmed by slit\-skin smear will be included.
Exclusion Criteria
- •1\.Pregnancy
- •2\.Breast feeding
- •3\.Known renal impairment
- •4\.Known liver impairment
- •5\.Congestive cardiac failure
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
N/A
Double-blind, double-dummy, randomised, comparative, multi-centre phase III study on the efficacy and tolerability of an 8-week oral treatment with 9 mg budesonide once daily vs. 3 mg budesonide three-times daily in patients with active Crohn’s disease - 9 mg budesonide OD vs. 3 mg budesonide TID in active Crohn’s diseaseEUCTR2008-006957-42-LVDr. Falk Pharma GmbH400
Active, Not Recruiting
N/A
Double-blind, double-dummy, randomised, comparative, multi-centre phase III study on the efficacy and tolerability of an 8-week oral treatment with 9 mg budesonide once daily vs. 3 mg budesonide three-times daily in patients with active Crohn’s disease - 9 mg budesonide OD vs. 3 mg budesonide TID in active Crohn’s diseaseInduction of remission in active Crohn´s diseaseMedDRA version: 14.0Level: LLTClassification code 10058815Term: Crohn's disease acute episodeSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 14.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2008-006957-42-LTDr. Falk Pharma GmbH500
Active, Not Recruiting
N/A
Double-blind, double-dummy, randomised, comparative, multi-centre phase III study on the efficacy and tolerability of an 8-week oral treatment with 9 mg budesonide once daily vs. 3 mg budesonide three-times daily in patients with active Crohn’s disease - 9 mg budesonide OD vs. 3 mg budesonide TID in active Crohn’s diseaseInduction of remission in active Crohn´s diseaseMedDRA version: 12.0Level: LLTClassification code 10058815Term: Crohn's disease acute episodeMedDRA version: 12.0Level: PTClassification code 10011401Term: Crohn's diseaseEUCTR2008-006957-42-HUDr. Falk Pharma GmbH400
Active, Not Recruiting
N/A
Double-blind, double-dummy, randomised, comparative, multi-centre phase III study on the efficacy and tolerability of an 8-week oral treatment with 9 mg budesonide once daily vs. 3 mg budesonide three-times daily in patients with active Crohn’s disease - 9 mg budesonide OD vs. 3 mg budesonide TID in active Crohn’s diseaseInduction of remission in active Crohn´s diseaseMedDRA version: 12.0Level: LLTClassification code 10058815Term: Crohn's disease acute episodeMedDRA version: 12.0Level: PTClassification code 10011401Term: Crohn's diseaseEUCTR2008-006957-42-SKDr. Falk Pharma GmbH400
Active, Not Recruiting
N/A
Double-blind, double-dummy, randomised, comparative, multi-centre phase III study on the efficacy and tolerability of an 8-week oral treatment with 9 mg budesonide once daily vs. 3 mg budesonide three-times daily in patients with active Crohn’s disease - 9 mg budesonide OD vs. 3 mg budesonide TID in active Crohn’s diseaseInduction of remission in active Crohn´s diseaseMedDRA version: 12.0Level: LLTClassification code 10058815Term: Crohn's disease acute episodeMedDRA version: 12.0Level: PTClassification code 10011401Term: Crohn's diseaseEUCTR2008-006957-42-CZDr. Falk Pharma GmbH400